Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Sonneveld on the Potential of Quadruplet Therapy Regimens in Multiple Myeloma

August 22nd 2024

Pieter Sonneveld, MD, PhD, discusses the potential of quadruplet therapeutic regimens in the frontline management of multiple myeloma.

Dr Mohty on the Potential Role of BCMA-Targeted Bispecific Antibodies in Myeloma

August 22nd 2024

Mohamad Mohty, MD, PhD, discusses the potential role of BCMA-targeted bispecific antibodies in myeloma.

FDA Issues Complete Response Letter to Linvoseltamab BLA in R/R Multiple Myeloma

August 21st 2024

The FDA has issued a CRL to the BLA seeking approval of linvoseltamab for use in select patients with relapsed or refractory multiple myeloma.

Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

August 21st 2024

The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.

Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

August 21st 2024

The key opinion leaders examine selinexor combinations and dosing strategies they currently employ, while also addressing how the frequency of treatment-related adverse events (TRAEs) associated with selinexor varies with lower dosing regimens in the context of managing early relapse multiple myeloma.

Dr Sonneveld on the FDA Approval of Subcutaneous Daratumumab Plus VRd in Myeloma

August 20th 2024

Pieter Sonneveld, MD, PhD, discusses the FDA approval of daratumumab plus VRd for select patients with newly diagnosed multiple myeloma.

Dr Hernandez-Ilizaliturri on the Use of CAR T-Cell Therapy in R/R Multiple Myeloma

August 19th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr Banerjee on Selecting Between Bispecific and CAR T-Cell Treatments in Myeloma

August 16th 2024

Rahul Banerjee, MD, FACP, discusses factors that may inform treatment selection when choosing between bispecific antibodies and CAR T-cell therapies in multiple myeloma

Linvoseltamab Demonstrates Deep, Durable Responses in R/R Myeloma Ahead of FDA Action Date

August 15th 2024

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple Myeloma

August 15th 2024

Suzanne Trudel, MSc, MD, discusses the implications of results from the DREAMM-7 and DREAMM-8 trials in relapsed/refractory multiple myeloma.

Clinical Insights on Next Treatment Approach Steps

August 14th 2024

A panel of experts in relapsed/refractory multiple myeloma analyzes a patient case, detailing their clinical approach to optimize outcomes for a 68-year-old male presenting with early relapse multiple myeloma.

Clinical Scenario I: 68-yr Old Man with Early Relapse MM

August 14th 2024

Key opinion leaders present a clinical patient scenario involving a 68-year-old male patient presenting with early relapse multiple myeloma.

Elranatamab Shows Activity, Safety as Compassionate Use in R/R Multiple Myeloma

August 13th 2024

Mohamad Mohty, MD, PhD, discusses real-world data for elranatamab in relapsed/refractory multiple myeloma in the French compassionate use program.

Dr Jagannath on the Potential Utility of Linvoseltamab in R/R Multiple Myeloma

August 12th 2024

Sundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Dr Krishnan on the Evolving Role of Belantamab Mafodotin in Multiple Myeloma

August 12th 2024

Amrita Krishnan, MD, discusses the evolving role of belantamab mafodotin in the treatment of multiple myeloma.

Isatuximab Plus VRd Improves PFS in Transplant-Eligible, Newly Diagnosed Myeloma

August 8th 2024

Isatuximab plus VRd induction improved progression-free survival in transplant-eligible, newly diagnosed multiple myeloma.

Dr Lentzsch on Results for Linvoseltamab in Heavily Pretreated R/R Myeloma

August 7th 2024

Suzanne Lentzsch, MD, PhD discusses data for linvoseltamab in patients with relapsed/refractory multiple myeloma

Dr Banerjee on the Evolving Multiple Myeloma Treatment Paradigm

August 6th 2024

Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma.

Dr Battiwalla on Addressing Unmet Needs in Multiple Myeloma

August 5th 2024

Minoo Battiwalla, MD, discusses remaining unmet needs for patients with multiple myeloma and potential strategies being explored to address these needs.

BCMA/CD19–Targeting CAR T-Cell Therapy Is Effective in Newly Diagnosed Multiple Myeloma

August 2nd 2024

The BCMA/CD19–targeted CAR T-cell therapy GC012F was safe and produced favorable outcomes in newly diagnosed multiple myeloma after induction therapy.